92 studies found for:    Heart Block | Open Studies | NIH, U.S. Fed
Show Display Options
Rank Status Study
21 Recruiting Antibody Treatment for Advanced Celiac Disease
Conditions: Celiac Disease;   Celiac Sprue;   Gluten Enteropathy;   Gluten-Sensitive Enteropathy
Intervention: Biological: Hu-Mik- Beta-1
22 Recruiting Randomized Endo-Vein Graft Prospective
Condition: Coronary Artery Bypass Grafting
Intervention: Procedure: Vein Harvesting Procedures
23 Recruiting Pathophysiology of Orthostatic Intolerance
Conditions: Tachycardia;   Postural Orthostatic Tachycardia Syndrome
Interventions: Radiation: DAXOR;   Procedure: QSweat;   Drug: Intrinsic Heart Rate
24 Recruiting Lidocaine For Neuroprotection During Cardiac Surgery
Condition: Cognitive Decline
Interventions: Drug: Lidocaine;   Drug: Placebo
25 Recruiting Longitudinal Observational Study of Severe Asthma
Condition: Asthma
Intervention:
26 Unknown  Prevalence of Chagas Disease in Immigrant Patients With Conduction Abnormalities on Electrocardiogram
Condition: Chagas Disease
Intervention: Procedure: Trypanosoma cruzi serology
27 Recruiting Identification of Patient Phenotypes Associated With Elevated Aldosterone Levels
Condition: Acute Heart Failure
Intervention:
28 Recruiting PAHTCH (Carvedilol)
Condition: Pulmonary Hypertension
Interventions: Drug: Carvedilol;   Drug: Carvedilol placebo
29 Recruiting Natural History of Sickle Cell Disease and Other Hemolytic Disorders
Conditions: Hemoglobin SC Disease;   Hematologic Diseases;   Sickle Cell Anemia;   Hemolytic Anemia
Intervention:
30 Recruiting Hydroxyurea in Pulmonary Arterial Hypertension
Condition: Pulmonary Hypertension
Intervention: Drug: Hydroxyurea
31 Recruiting Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Condition: Lung Cancer
Interventions: Biological: bevacizumab;   Drug: pemetrexed disodium
32 Recruiting Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
Conditions: Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
Interventions: Drug: ibrutinib;   Biological: rituximab;   Drug: bendamustine hydrochloride;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
33 Recruiting Ultrasound and Other Images of Artery Blockages
Condition: Atherosclerosis
Intervention:
34 Recruiting Myocardial Perfusion and Scarring in Congenital Heart Disease
Condition: Congenital Heart Disease
Intervention:
35 Recruiting Cardiovascular Disease Screening
Conditions: Congenital Heart Disease;   Atherosclerosis;   Myocardial Ischemia;   Myocardial Infarction;   Acquired Heart Disease
Intervention:
36 Recruiting Evaluating New Radiation Techniques for Cardiovascular Imaging
Condition: Coronary Disease
Intervention:
37 Recruiting S0819: Carboplatin/Paclitaxel With or Without Bevacizumab and/or Cetuximab in Stage IV or Recurrent Non-Small Cell Lung Cancer
Condition: Lung Cancer
Interventions: Biological: bevacizumab;   Biological: cetuximab;   Drug: carboplatin;   Drug: paclitaxel
38 Recruiting Heart Imaging in Children With Muscular Dystrophy
Condition: Muscular Dystrophy
Intervention:
39 Recruiting Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Salivary Gland Squamous Cell Carcinoma;   Stage IV Salivary Gland Cancer;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IVA Salivary Gland Cancer;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Salivary Gland Cancer;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Verrucous Carcinoma of the Larynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Stage IVC Salivary Gland Cancer;   Stage IVC Squamous Cell Carcinoma of the Larynx;   Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Oropharynx;   Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Verrucous Carcinoma of the Larynx;   Stage IVC Verrucous Carcinoma of the Oral Cavity;   Tongue Cancer;   Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions: Drug: docetaxel;   Drug: cisplatin;   Drug: carboplatin;   Drug: fluorouracil;   Biological: bevacizumab;   Other: laboratory biomarker analysis;   Other: cytology specimen collection procedure
40 Recruiting Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-positive Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: doxorubicin hydrochloride;   Drug: docetaxel;   Drug: cyclophosphamide;   Biological: trastuzumab;   Drug: paclitaxel;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years